Amoytop Biotech - Public Comps and Valuation Multiples

Amoytop Biotech Overview

About Amoytop Biotech

Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.

Founded

1996

HQ

Employees

n/a

Website

amoytop.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $496M

LTM EBITDA $148M

EV

$4.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Amoytop Biotech Financials

As of September 2025, Amoytop Biotech reported last 12-month revenue of $496M and EBITDA of $148M.

In the same period, Amoytop Biotech generated $464M in LTM gross profit and $145M in net income.

See Amoytop Biotech valuation multiples based on analyst estimates

Amoytop Biotech P&L

In the most recent fiscal year, Amoytop Biotech reported revenue of $395M and EBITDA of $141M.

Amoytop Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Amoytop Biotech valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$496M	XXX	$395M	XXX	XXX	XXX
Gross Profit	$464M	XXX	$369M	XXX	XXX	XXX
Gross Margin	94%	XXX	93%	XXX	XXX	XXX
EBITDA	$148M	XXX	$141M	XXX	XXX	XXX
EBITDA Margin	30%	XXX	36%	XXX	XXX	XXX
EBIT	$172M	XXX	$136M	XXX	XXX	XXX
EBIT Margin	35%	XXX	34%	XXX	XXX	XXX
Net Profit	$145M	XXX	$116M	XXX	XXX	XXX
Net Margin	29%	XXX	29%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Amoytop Biotech including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $496M. EBITDA for the last twelve months was $148M. In the most recent fiscal year, Amoytop Biotech achieved $395M in revenue and $141M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$496M	Analyst estimates available to subscribers	$395M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$464M	Analyst estimates available to subscribers	$369M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	93.6% gross margin	Analyst estimates available to subscribers	93.5% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$148M	Analyst estimates available to subscribers	$141M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	29.9% EBITDA margin	Analyst estimates available to subscribers	35.7% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$172M	Analyst estimates available to subscribers	$136M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	34.6% EBIT margin	Analyst estimates available to subscribers	34.3% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$145M	Analyst estimates available to subscribers	$116M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	29.2% net profit margin	Analyst estimates available to subscribers	29.4% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Amoytop Biotech

This financial data table provides comprehensive performance metrics for Amoytop Biotech, a company based in China. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Amoytop Biotech generated $496M in revenue over the last twelve months.
The company achieved $148M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $464M.
Net income over the last twelve months reached $145M.

Fiscal Year Performance

In the most recent fiscal year, Amoytop Biotech reported $395M in total revenue.
Fiscal year EBITDA was $141M.
The company maintained a gross profit margin of 93.5% in the most recent fiscal year.
EBITDA margin for the fiscal year was 35.7%.
Net profit margin reached 29.4% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Amoytop Biotech. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Amoytop Biotech Stock Performance

Amoytop Biotech has current market cap of CNY 31.6B (or $4.4B), and EV of CNY 30.9B (or $4.3B).

Market Cap Evolution

Amoytop Biotech Stock Data

As of October 17, 2025, Amoytop Biotech's stock price is CNY 78 (or $11).

See Amoytop Biotech trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$4.3B	$4.4B	XXX	XXX	XXX	XXX	$0.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Amoytop Biotech Valuation Multiples

Amoytop Biotech's trades at 11.0x EV/Revenue multiple, and 30.7x EV/EBITDA.

See valuation multiples for Amoytop Biotech and 15K+ public comps

Amoytop Biotech Financial Valuation Multiples

As of October 17, 2025, Amoytop Biotech has market cap of $4.4B and EV of $4.3B.

Equity research analysts estimate Amoytop Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Amoytop Biotech has a P/E ratio of 30.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$4.4B	XXX	$4.4B	XXX	XXX	XXX
EV (current)	$4.3B	XXX	$4.3B	XXX	XXX	XXX
EV/Revenue	8.7x	XXX	11.0x	XXX	XXX	XXX
EV/EBITDA	29.3x	XXX	30.7x	XXX	XXX	XXX
EV/EBIT	25.2x	XXX	32.0x	XXX	XXX	XXX
EV/Gross Profit	9.3x	XXX	n/a	XXX	XXX	XXX
P/E	30.6x	XXX	38.2x	XXX	XXX	XXX
EV/FCF	35.1x	XXX	172.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Amoytop Biotech Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Amoytop Biotech Margins & Growth Rates

Amoytop Biotech's last 12 month revenue growth is 32%

Amoytop Biotech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.

Amoytop Biotech's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Amoytop Biotech's rule of X is 111% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Amoytop Biotech and other 15K+ public comps

Amoytop Biotech Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	32%	XXX	32%	XXX	XXX	XXX
EBITDA Margin	30%	XXX	36%	XXX	XXX	XXX
EBITDA Growth	n/a	XXX	n/a	XXX	XXX	XXX
Rule of 40	66%	XXX	68%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	111%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	n/a	XXX	XXX	XXX
Opex per Employee	XXX	XXX	n/a	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	27%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	10%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	59%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial